Skip to content
OpenCapital
Get started

Cullinan Therapeutics, Inc. CGEM Q2 2025 earnings

Reported August 7, 2025 · Before market open

EPS-$1.07Miss by $0.24
EPS estimate-$0.83

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$3.7M
EPS estimate-$0.80

Financials

Q2 2025

Income statement

See full
Operating income-$75.8M-51.5%
Net income-$70.1M-66.7%

Balance sheet

See full
Cash & equivalents$72.8M-36.7%
Total debt$1.5M-44.4%
Total equity$492.1M-25.0%
Total assets$520.3M-23.6%

Cash flow

See full
Operating cash flow-$57.6M-58.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$462.67M-38.3%
Enterprise value$391.37M-38.6%

Returns & leverage

See full
Return on equity-36%+31.2pp
Debt / equity0×0.0×
Current ratio9.8×-19.0×

Versus estimates

Diluted EPS

Q1 2026-$0.75Beat by $0.09Q4 2025-$0.77Beat by $0.03Q3 2025-$0.77Beat by $0.18
Q2 2025-$1.07Miss by $0.24
Q1 2025-$0.74Beat by $0.04Q4 2024-$0.73Beat by $0.02

Ask the moment Cullinan Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cullinan Therapeutics, Inc. report Q2 2025 earnings?
Cullinan Therapeutics, Inc. (CGEM) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Cullinan Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Cullinan Therapeutics, Inc. reported eps of $-1.07 for Q2 2025.
Did Cullinan Therapeutics, Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.83 by $0.24.
How did Cullinan Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 42.7% from $-0.75.
Where can I find Cullinan Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-104551) directly on SEC EDGAR. The filing index links above go to sec.gov.